• If you are wondering whether Moderna's current share price reflects its true worth, you are not alone. Many investors are asking the same question as the market reassesses the mRNA pioneer.
• The stock recently closed at US$54.98, with returns of 10.3% over 7 days, 34.1% over 30 days and 78.2% year to date, while the 1 year return is 62.9% and the 3 and 5 year returns are 63.7% and 64.8% declines respectively.
• Recent headlines have focused on Moderna's mRNA platform and its pipeline beyond Covid vaccines, which has kept investor attention on the company's longer term prospects rather than short term catalysts. This broader context helps frame the sharp moves in the share price as the market reassesses how much future optionality to factor into today's valuation.
• Even so, Moderna currently scores only 1 out of 6 on our valuation checks. Next we will look at the usual models investors rely on to judge value, before turning to a more complete way to think about what the stock might be worth.

Moderna scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Moderna Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model looks at the cash Moderna is expected to generate in the future and discounts those projections back to today to estimate what the business might be worth now.

For Moderna, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is a loss of about US$2.19b. Analysts provide estimates out to 2030, where free cash flow is projected at US$254 million, and further projections out to 2035 are extrapolated rather than directly forecast by analysts.

Putting these projections together, the DCF model arrives at an estimated intrinsic value of about US$27.27 per share. Compared with the recent share price of US$54.98, this implies the stock is 101.6% overvalued according to this model.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Moderna may be overvalued by 101.6%. Discover 48 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Moderna Price vs Sales

For companies where earnings are not the main focus, the preferred multiple is often the P/S ratio, because it compares the market value of the business to the revenue it is generating. It is a simple way to think about what investors are paying for each dollar of sales.

What counts as a normal or fair P/S ratio depends on how the market views a company’s growth potential and risk. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk usually means a lower one.

Moderna currently trades on a P/S ratio of 11.17x. This is close to the Biotechs industry average P/S of 12.41x, but well above the peer group average of 4.73x. Simply Wall St’s Fair Ratio for Moderna is 1.37x, which reflects a preferred multiple that accounts for factors such as the company’s earnings profile, its industry, profit margins, market cap and key risks. This makes the Fair Ratio a more tailored benchmark than a simple comparison with peers or the wider industry. Against this yardstick, Moderna’s current P/S of 11.17x screens as materially higher than the Fair Ratio.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Moderna Narrative

Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives, a simple way for you to write the story you believe about Moderna, link that story to your own forecasts for revenue, earnings and margins, and arrive at a Fair Value you can compare to today’s price on Simply Wall St’s Community page. On that page, different Narratives update automatically when new news or earnings land and can range from very optimistic views that see Moderna’s Fair Value around US$175 per share to far more cautious takes closer to US$15. This gives you a clear, visual sense of how different perspectives on the same company can lead to very different decisions about whether the stock looks expensive or cheap to you right now.

For Moderna however we will make it really easy for you with previews of two leading Moderna Narratives:

Fair value in this bull case: US$175.00 per share

Implied discount to this fair value at US$54.98: about 68.6% undervalued

Revenue growth assumption used: 48.43%

• Views Moderna as having a strong balance sheet, trading below book value and backed by substantial assets built up during the Covid period.
• Argues that the pullback from the pandemic share price peak is an overreaction, with the company framed as being in a transition period while its broader mRNA pipeline moves through trials.
• Positions Moderna as a relatively lower risk biotech in this narrative, with multiple shots on goal in the pipeline and a value oriented angle based on assets and reinvested cash flows.

Fair value in this bear case: US$38.80 per share

Implied premium to this fair value at US$54.98: about 29.0% overvalued

Revenue growth assumption used: 11.47%

• Highlights that analyst expectations rely on revenue growth, margin improvement and a future P/E of 36.81x, which is higher than the current P/E for the wider US Biotechs industry cited in the narrative.
• Flags risks around slower vaccine sales, competition, policy changes, cost cuts and capital constraints, which could affect revenue stability, pipeline breadth and earnings.
• Frames the consensus fair value and price target as sensitive to execution on the cancer and vaccine pipeline, regulatory outcomes and public sentiment toward vaccines.

If you want to see how your own view compares with these takes, you can use the full set of community Narratives to test different assumptions on growth, margins and fair value, then decide where Moderna fits in your portfolio.

Do you think there's more to the story for Moderna? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.